StockNews.AISignal intelligence
Aprea Therapeutics, Inc. · NASDAQ · Healthcare
Browse public APRE signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Aprea Therapeutics (APRE) shares surged after the announcement of new preliminary data from its ongoing Phase 1 trial of the WEE1 kinase inhibitor APR-1051. This development may bolster the company's attractiveness to investors, highlighting potential progress in its drug candidate pipeline.
View signal analysisDecember sees increased interest in low-priced stocks like APRE. APRE focuses on precision oncology programs for DNA repair and cancer pathways. No recent clinical updates for APRE, but still a watch by traders. Market volatility may lead to high movements in stocks like APRE. Year-end catalysts are fueling trader focus on $1 stocks, including APRE.
View signal analysisAprea reports encouraging Q3 clinical progress across WEE1 and ATR programs. APR-1051: 3 of 4 heavily pretreated patients achieved stable disease. ATRN-119 identified RP2D at 1,100 mg once daily; moving to combos. Maxim Group initiated Buy with $10 twelve-month price target; $13.7M cash runway.
View signal analysis